Rocakinogene Sifuplasmid
Chronic Hepatitis
National Cancer Institute (NCI)vaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Chronic Hepatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Meperidine Erasme University Hospital | Phase 4 | BB |
MIDAZOLAM Erasme University Hospital | Phase 4 | BB |
Orlistat St. Louis University | Phase 4 | BB |
Entecavir Cttq | Phase 4 | BB |
total glucosides of paeony West China Hospital | Phase 4 | BB |
View all 31 →
Same molecule, other indications
Rocakinogene Sifuplasmid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →